Shore, Neal D.
Mehlhaff, Bryan A.
Cookson, Michael S.
Saltzstein, Daniel R.
Tutrone, Ronald
Brown, Bruce
Lu, Sophia
Fallick, Mark
Hanson, Sarah
Saad, Fred
Clinical trials referenced in this document:
Documents that mention this clinical trial
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
https://doi.org/10.1007/s12325-023-02634-7
Article History
Received: 4 June 2023
Accepted: 1 August 2023
First Online: 15 September 2023
Declarations
:
: Neal D. Shore—Consulting or Advisory Role: Bayer, Janssen Scientific Affairs, Dendreon, Tolmar, Ferring, Medivation/Astellas, Amgen, Pfizer, AstraZeneca, Genentech, Myovant Sciences. Speakers’ Bureau: Janssen, Bayer, Dendreon. Bryan A. Mehlhaff—Honoraria, travel, and accommodation expenses, and acted as an advisor/consultant for Astellas, Amgen, Bayer, Janssen, and Pfizer; and has received grants/funding from Astellas, Bayer, Janssen, and Pfizer. Michael S. Cookson—Honoraria: Merck, Janssen Biotech, Bayer, Astellas Pharma, Myovant Sciences. Consulting or Advisory Role: Merck, Janssen Biotech, MDxHealth, Bayer, Astellas Pharma, Myovant Sciences, TesoRx Pharma, Genomic Health, Ferring Pharmaceuticals, Precision Biopsy. Daniel R. Saltzstein—No relevant conflicts. Ronald Tutrone—Advisory/Consulting role: Astellas, Pfizer, Myovant, Janssen, Biotechne, Nymox, Dendreon. Speaker: Biotechne, Astellas, Pfizer, Myovant. Bruce Brown; Sophia Lu—Employees of Myovant. Mark Fallick—Employed at Myovant at the time of research and manuscript development. Sarah Hanson—Employee of Pfizer. Fred Saad—Advisory roles for Astellas Pharma, AstraZeneca/MedImmune, Bayer, Janssen Oncology, and Sanofi; has received honoraria from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Janssen Oncology, and Sanofi; and has received research funding grants provided to the institution from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Pfizer, and Sanofi.
: The trial was approved by the institutional review board or independent ethics committee at each center and was conducted in accordance with the requirements of the regulatory authorities of each country and with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation. All patients provided written informed consent.